IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
07. August 2024 17:04 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
06. Mai 2024 11:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
IMUNON Reports Compliance with Nasdaq Listing Requirements
11. April 2024 08:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated...
IMUNON Announces Leadership Change
12. März 2024 17:00 ET
|
Imunon, Inc.
Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged. LAWRENCEVILLE, N.J., March 12, 2024 ...
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
27. Februar 2024 08:30 ET
|
Imunon, Inc.
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
07. November 2023 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
14. August 2023 08:30 ET
|
Imunon, Inc.
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
10. August 2023 08:00 ET
|
Imunon, Inc.
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at...
IMUNON’s CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention
08. Juni 2023 08:30 ET
|
Imunon, Inc.
Dr. Corinne Le Goff highlights clinical progress across the Company’s pipeline, provides context on the promise of DNA as a therapeutic and a vaccine LAWRENCEVILLE, N.J., June 08, 2023 (GLOBE...
IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023
04. Mai 2023 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...